Market cap
$286,067 Mln
Revenue (TTM)
$62,168 Mln
P/E Ratio
26.1
P/B Ratio
5.5
Div. Yield
1.8 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 3.96 | 5.28 | 6.95 | 11.38 | 13.63 |
| EBIT | 33.60 | 17.47 | 14.31 | 21.65 | 39.93 |
| Net Profit | 22.77 | 21.55 | 16.93 | 23.05 | 49.50 |
| EPS | 22.68 | 21.49 | 16.91 | 23.04 | 40.91 |
| Book Value | -- | -- | 19.32 | 9.46 | 21.23 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 20.57 | 14.61 | 24.07 | 24.00 | 19.18 |
| Net Margin
| -- | -- | 17.68 | -- | -- |
| Return on equity
| 18.72 | 13.04 | 22.20 | 22.93 | 17.60 |
| Return on Capital
| 10.93 | 7.56 | -- | 13.74 | 10.15 |
| Return on Assets
| 7.43 | 5.14 | 7.34 | 9.40 | 6.86 |
| Debt to Equity (x)
| -- | -- | 0.51 | 0.61 | 0.74 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
--
|
13.74
|
10.15
|
8.89
|
4.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
22.20
Higher than Peers by 37.13
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
22.20
|
22.93
|
17.60
|
15.63
|
8.62
|
|
Peer Median
|
-14.93
|
--
|
--
|
--
|
--
|
ROA
7.34
Higher than Peers by 10.83
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
7.34
|
9.40
|
6.86
|
6.03
|
3.26
|
|
Peer Median
|
-3.49
|
--
|
--
|
--
|
--
|
EBIT Margin
24.07
Higher than Peers by 23.13
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
24.07
|
24.00
|
19.18
|
18.53
|
8.64
|
|
Peer Median
|
0.94
|
--
|
--
|
--
|
--
|
Net Margin
17.68
Higher than Peers by 33.13
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
17.68
|
17.46
|
13.01
|
13.00
|
7.41
|
|
Peer Median
|
-15.46
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
6.95
Higher than Peers by 2.68
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
6.95
|
0.09
|
0.18
|
0.03
|
0.19
|
|
Peer Median
|
4.27
|
--
|
--
|
--
|
--
|
EBIT Growth
14.31
Higher than Peers by 66.38
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
14.31
|
35.89
|
22.21
|
121.56
|
278.93
|
|
Peer Median
|
-52.08
|
--
|
--
|
--
|
--
|
Net Profit Growth
16.93
Lower than Peers by 4.10
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
16.93
|
45.77
|
18.14
|
81.11
|
2,835.71
|
|
Peer Median
|
21.03
|
--
|
--
|
--
|
--
|
EPS Growth
16.91
Higher than Peers by 4.57
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
16.91
|
0.46
|
0.18
|
0.81
|
28.13
|
|
Peer Median
|
12.34
|
--
|
--
|
--
|
--
|
Book Value Growth
12.60
Higher than Peers by 14.75
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
12.60
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-2.15
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.51
Lower than Peers by 0.29
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
0.51
|
0.61
|
0.74
|
0.73
|
0.79
|
|
Peer Median
|
0.80
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.10
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
0.10
|
0.07
|
0.06
|
0.14
|
0.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.01
Lower than Peers by 0.28
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
1.01
|
0.94
|
0.93
|
0.82
|
0.86
|
|
Peer Median
|
1.29
|
--
|
--
|
--
|
--
|
Quick Ratio
0.79
Lower than Peers by 0.39
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
0.79
|
0.72
|
0.74
|
0.64
|
0.68
|
|
Peer Median
|
1.17
|
--
|
--
|
--
|
--
|
Interest Coverage
8.48
Higher than Peers by 8.18
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
8.48
|
8.32
|
6.17
|
5.34
|
2.88
|
|
Peer Median
|
0.30
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
26.30
Higher than Peers by 14.00
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
26.30
|
25.84
|
20.78
|
18.35
|
20.73
|
|
Peer Median
|
12.30
|
--
|
--
|
--
|
--
|
Asset Turnover
0.42
Higher than Peers by 0.11
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
0.42
|
0.54
|
0.53
|
0.46
|
0.44
|
|
Peer Median
|
0.31
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
--
|
82.12
|
66.34
|
70.16
|
71.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
--
|
203.44
|
191.66
|
223.60
|
201.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
--
|
496.71
|
123.58
|
128.49
|
79.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
--
|
-211.15
|
134.42
|
165.27
|
193.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
26.09
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
26.09
|
14.00
|
14.55
|
17.65
|
32.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
5.53
Higher than Peers by 4.94
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
5.53
|
2.95
|
2.51
|
2.69
|
2.85
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Dividend Yield
1.75
Higher than Peers by 1.32
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
1.75
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.44
|
--
|
--
|
--
|
--
|
EV/EBITDA
14.77
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
14.77
|
8.45
|
8.22
|
9.53
|
14.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
286,067
Higher than Peers by 285,601
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AstraZeneca - ADR
|
286,067
|
--
|
--
|
--
|
--
|
|
Peer Median
|
466
|
--
|
--
|
--
|
--
|